ImpriMed, Inc. is a precision medicine company developing AI-driven drug response prediction technologies for cancer care. Its platform analyzes patient and tumor characteristics to help veterinarians and clinicians identify potentially effective treatments, reduce unnecessary costs, accelerate therapy decisions, and improve outcomes in canine, feline, and human oncology.
Leadership & Board
Current Number of Employees44
Current LinkedIn Followers5,814
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$10M
Total Amount Raised$10M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$10M
Latest Funding Amount$10M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 24, 2026
Series A
$10.00M
―
Similar Companies
A snapshot of private companies similar to ImpriMed Inc, helping you discover and navigate related company profiles.